Emergent BioSolutions Inc
EBS
View Detailed Chart
12.430USD
-0.200-1.58%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
655.06MMarket Cap
8.75P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.58%
5 Days
+0.08%
1 Month
+12.49%
6 Months
+95.75%
Year to Date
+30.02%
1 Year
+50.30%
View Detailed Chart
TradingKey Stock Score of Emergent BioSolutions Inc
Currency: USD Updated: 2025-12-26Key Insights
Emergent BioSolutions Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 53/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Emergent BioSolutions Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
13.500
Target Price
+13.73%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Emergent BioSolutions Inc Highlights
StrengthsRisks
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Overvalued
The company’s latest PE is 8.75, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 39.86M shares, increasing 0.32% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 17.08K shares of this stock.
Emergent BioSolutions Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Emergent BioSolutions Inc Info
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Ticker SymbolEBS
CompanyEmergent BioSolutions Inc
CEOPapa (Joseph C)
Websitehttps://emergentbiosolutions.com/
FAQs
What is the current price of Emergent BioSolutions Inc (EBS)?
The current price of Emergent BioSolutions Inc (EBS) is 12.430.
What is the symbol of Emergent BioSolutions Inc?
The ticker symbol of Emergent BioSolutions Inc is EBS.
What is the 52-week high of Emergent BioSolutions Inc?
The 52-week high of Emergent BioSolutions Inc is 13.410.
What is the 52-week low of Emergent BioSolutions Inc?
The 52-week low of Emergent BioSolutions Inc is 4.020.
What is the market capitalization of Emergent BioSolutions Inc?
The market capitalization of Emergent BioSolutions Inc is 655.06M.
What is the net income of Emergent BioSolutions Inc?
The net income of Emergent BioSolutions Inc is -190.60M.
Is Emergent BioSolutions Inc (EBS) currently rated as Buy, Hold, or Sell?
According to analysts, Emergent BioSolutions Inc (EBS) has an overall rating of Buy, with a price target of 13.500.
What is the Earnings Per Share (EPS TTM) of Emergent BioSolutions Inc (EBS)?
The Earnings Per Share (EPS TTM) of Emergent BioSolutions Inc (EBS) is 1.421.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%Popular Symbols
